| Trial | control | p<0.05 | harm | NS |
|---|
| Chiche, 1979 | nitroglycerin vs control | | | death 0.34 [0.10; 1.19] |
| Bussman, 1981 | nitroglycerin vs control | death 0.31 [0.11; 0.86] | | early death 0.37 [0.08; 1.78] |
| Flaherty, 1983 | nitroglycerin vs placebo | | | death 0.86 [0.41; 1.80] early death 0.49 [0.15; 1.57] |
| Nelson, 1983 | nitroglycerin vs control | | | death NaN [NaN; NaN] early death NaN [NaN; NaN] |
| Jaffe, 1983 | nitroglycerin vs placebo | | | death 2.00 [0.38; 10.49] early death 0.48 [0.15; 1.55] |
| Lis, 1984 | nitroglycerin vs placebo | | | death 0.59 [0.21; 1.65] early death 0.59 [0.15; 2.28] |
| Jugdutt, 1983 | nitroglycerin vs control | death 0.55 [0.35; 0.86] | | early death 0.50 [0.05; 4.75] |
| GISSI-3, 1994 | nitroglycerin vs control | deaths at 2 days 0.82 [0.68; 0.99] | | early death 0.93 [0.82; 1.05] |
| Charvat, 1990 | nitroglycerin vs placebo | | | early death 1.08 [0.33; 3.55] |
| Jugdutt, 1988 | nitroglycerin vs control | early death 0.24 [0.11; 0.54] | | |
| Trial | Treatments | Patients | Method |
|---|
| Chiche, 1979 | Nitroglycerin IV for 7 days (n=50) vs. placebo (n=45) | patients with suspected myocardial infarction, within 12 h of the onset | single blind Parallel groups Sample size: 50/45 Primary endpoint: FU duration: in hospital (28d) |
| Bussman, 1981 | i.v. nitroglycerin for 48 hours (n=31) vs. no i.v. nitroglycerin (n=29) | patients with acute myocardial infarction within 24 hours | open Parallel groups Sample size: 31/29 Primary endpoint: infarct size FU duration: 18 months |
| Flaherty, 1983 | Nitroglycerin for 48h (n=56) vs. placebo (n=48) | patients with acute myocardial infarction | single blind Parallel groups Sample size: 56/48 Primary endpoint: FU duration: 15 months |
| Nelson, 1983 | intravenous isosorbide dinitrate (50-200 micrograms/kg/h) (n=14) vs. frusemide (1 mg/kg) (n=14) | men with radiographic and haemodynamic evidence of left ventricular failure following acute myocardial infarction | single blind Parallel groups Sample size: 14/14 Primary endpoint: FU duration: in hospital |
| Jaffe, 1983 | glyceryl trinitrate titrated (n=57) vs. placebo (n=57) | patients with inferior infarction under conventional clinical conditions within 10 hours of the onset of symptoms | double blind Parallel groups Sample size: 57/57 Primary endpoint: FU duration: in hospital |
| Lis, 1984 | 48-h intravenous infusion of nitroglycer (n=64) vs. placebo (n=76) | patients with acute myocardial infarction | double blind Parallel groups Sample size: 64/76 Primary endpoint: FU duration: 4 months |
| Jugdutt, 1983 | Intravenous nitroglycerin (n=154) vs. control (n=156) | patients with acute myocardial infarction | open Parallel groups Sample size: 154/156 Primary endpoint: FU duration: 3 months |
| GISSI-3, 1994 | nitrates intravenous for the first 24 h followed by transdermal transdermal glyceryl trinitrate nitrates 10 mg daily (n=9663) vs. control (n=9655) | patients with acute myocardial infarction | open Parallel groups Sample size: 9663/9655 Primary endpoint: Italy FU duration: 6 week |
| Charvat, 1990 | intravenous nitroglycerin for 48h (n=62) vs. placebo (n=67) | patients with acute myocardial infarction and ST segment elevation on admission but no Q wave in the infarcted area within 6 hours of onset | double blind Parallel groups Sample size: 62/67 Primary endpoint: FU duration: 72 hours |
| Jugdutt, 1988 | intravenous nitroglycerin (n=154) vs. control (n=156) remarque traitement | acute myocardial infarction remarque patient | open Parallel groups Sample size: 154/156 Primary endpoint: FU duration: 12 mo remarque traitement |
